This mini-review highlights targeted therapies' effectiveness in breast cancer, emphasizing the challenges of resistance pathways and treatment toxicity.
Key Points
Targeted therapies improve survival rates in breast cancer, offering more focused treatment options.
Drugs like trastuzumab and PARP inhibitors show significant clinical efficacy across various breast cancer subtypes.
Resistance mechanisms and toxicities present challenges, making predictive biomarker identification essential.
Future advancements aim to integrate new technologies and immunotherapies for personalized cancer care.